Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company developing innovative drugs, subsidiary of Simcere.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for advanced breast cancer: experimental combo enters final testing
Disease control OngoingThis Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo aims to keep cancer fluid at bay
Disease control OngoingThis study tests whether adding Endostar to standard cisplatin treatment can help cancer patients with fluid buildup in the chest or belly (malignant pleural effusion or ascites) go longer without needing another drainage procedure. About 290 adults whose fluid has not been contr…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC